GLP‐1 RAs may be employed for the treatment of T2D, particularly in people with severe insulin resistance (SIRD) often associated with significant overweight.(18) Notably, GLP‐1 RAs have also received therapeutic approval for managing obesity in the absence of diabetes.(19) They can be used as monotherapy for weight management or in combination with GIP or amylin.(20, 21, 22) Currently, the following GLP1‐RAs are approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of T2D: dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide. The gene discussed is GLP1R; the disease is Insulin resistance.